Immunitybio Stock

Immunitybio EBIT

The EBIT of Immunitybio (IBRX) as of Jul 19, 2026 is -344.18 M USD. In the previous year, EBIT was -361.36 M USD — a change of -4.75% (higher).

EBIT

-344.18 MUSD

YoY

-4.75%

Last updated:

In 2026, Immunitybio's EBIT was -344.18 M USD, a -4.75% increase from the -361.36 M USD EBIT recorded in the previous year.

The Immunitybio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2024
-0.34 base
Jan 1, 2025 (e)
-0.26 base
Jan 1, 2026 (e)
-0.22 base
Jan 1, 2027 (e)
0.04 base
Jan 1, 2028 (e)
0.44 base
Jan 1, 2029 (e)
1.34 base
Jan 1, 2030 (e)
2.60 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (B USD)
2031 est -
2030 est 2.60
2029 est 1.34
2028 est 0.44
2027 est 0.04
2026 est -0.22
2025 est -0.26
2024 -0.34
2023 -0.36
2022 -0.35
2021 -0.33
2020 -0.21
2019 -0.16
2018 -0.10
2017 -0.10
2016 -0.12
2015 -0.24
2014 -0.01
2013 -0.00
Access this data via the Eulerpool API

Immunitybio Revenue

Immunitybio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14.75 M USD
-344.18 M USD
-413.56 M USD
Jan 1, 2025 (e)
115.02 M USD
-262.45 M USD
-288.77 M USD
Jan 1, 2026 (e)
218.93 M USD
-218.01 M USD
-204.84 M USD
Jan 1, 2027 (e)
546.00 M USD
36.49 M USD
-24.89 M USD
Jan 1, 2028 (e)
995.05 M USD
441.99 M USD
263.17 M USD
Jan 1, 2029 (e)
1.98 B USD
1.34 B USD
775.27 M USD
Jan 1, 2030 (e)
3.41 B USD
2.60 B USD
1.55 B USD
Jan 1, 2031 (e)
5.71 B USD
0.00 USD
2.78 B USD

Immunitybio Margins

Immunitybio stock margins

The Immunitybio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunitybio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunitybio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
100.00 %
-2,334.23 %
-2,804.77 %
Jan 1, 2025 (e)
100.00 %
-228.18 %
-251.06 %
Jan 1, 2026 (e)
100.00 %
-99.58 %
-93.57 %
Jan 1, 2027 (e)
100.00 %
6.68 %
-4.56 %
Jan 1, 2028 (e)
100.00 %
44.42 %
26.45 %
Jan 1, 2029 (e)
100.00 %
67.66 %
39.06 %
Jan 1, 2030 (e)
100.00 %
76.25 %
45.56 %
Jan 1, 2031 (e)
100.00 %
0.00 %
48.66 %

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Immunitybio's EBIT

Immunitybio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immunitybio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immunitybio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immunitybio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immunitybio stock

EBIT of Immunitybio is -344.18 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Immunitybio

All Key Metrics — Immunitybio